Literature DB >> 28785861

Response to letter to the editor referencing-2016 updated MASCC/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer.

Carla I Ripamonti1, Andrew Davies2, Eduardo Bruera3, Alex Molassiotis4, Declan Walsh5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28785861     DOI： 10.1007/s00520-017-3832-3

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  5 in total

1.  Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer.

Authors:  C Ripamonti; R Twycross; M Baines; F Bozzetti; S Capri; F De Conno; B Gemlo; T M Hunt; H B Krebs; S Mercadante; R Schaerer; P Wilkinson
Journal:  Support Care Cancer       Date:  2001-06       Impact factor: 3.603

2.  Octreotide for malignant bowel obstruction: commentary on Currow et al.

Authors:  Sebastiano Mercadante
Journal:  J Pain Symptom Manage       Date:  2015-04-08       Impact factor: 3.612

Review 3.  2016 Updated MASCC/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer.

Authors:  Declan Walsh; Mellar Davis; Carla Ripamonti; Eduardo Bruera; Andrew Davies; Alex Molassiotis
Journal:  Support Care Cancer       Date:  2016-08-17       Impact factor: 3.603

4.  Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.

Authors:  David C Currow; Stephen Quinn; Meera Agar; Belinda Fazekas; Janet Hardy; Nikki McCaffrey; Simon Eckermann; Amy P Abernethy; Katherine Clark
Journal:  J Pain Symptom Manage       Date:  2014-11-14       Impact factor: 3.612

5.  Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.

Authors:  Pascale Mariani; Joëlle Blumberg; Alain Landau; Daniela Lebrun-Jezekova; Estelle Botton; Olivier Beatrix; Didier Mayeur; Robert Herve; Pascal Maisonobe; Laure Chauvenet
Journal:  J Clin Oncol       Date:  2012-10-29       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.